UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 78

Sortiert nach

Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery

PloS one, 2009-07, Vol.4 (7), p.e6146-e6146

2009

Volltextzugriff (PDF)

Identification of recurrent SMO and BRAF mutations in ameloblastomas

Nature genetics, 2014-07, Vol.46 (7), p.722-725

2014

Volltextzugriff (PDF)

Recurrent rearrangements of the Myb/SANT-like DNA-binding domain containing 3 gene (MSANTD3) in salivary gland acinic cell carcinoma

PloS one, 2017-02, Vol.12 (2), p.e0171265-e0171265

2017

Volltextzugriff (PDF)

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial

Haematologica (Roma), 2022-09, Vol.107 (9), p.2108

2022

Volltextzugriff (PDF)

Integrative Genomics Implicates EGFR as a Downstream Mediator in NKX2-1 Amplified Non-Small Cell Lung Cancer

PloS one, 2015-11, Vol.10 (11), p.e0142061-e0142061

2015

Volltextzugriff (PDF)

Modulators of sensitivity and resistance to inhibition of PI3K identified in a pharmacogenomic screen of the NCI-60 human tumor cell line collection

PloS one, 2012-09, Vol.7 (9), p.e46518

2012

Volltextzugriff (PDF)

SMURF1 amplification promotes invasiveness in pancreatic cancer

PloS one, 2011-08, Vol.6 (8), p.e23924

2011

Volltextzugriff (PDF)

Genomic profiling identifies GATA6 as a candidate oncogene amplified in pancreatobiliary cancer

PLoS genetics, 2008-05, Vol.4 (5), p.e1000081-e1000081

2008

Volltextzugriff (PDF)

Genomic instability in breast cancer: Pathogenesis and clinical implications

Molecular oncology, 2010-06, Vol.4 (3), p.255-266

2010

Volltextzugriff (PDF)

CAMK1D amplification implicated in epithelial–mesenchymal transition in basal-like breast cancer

Molecular oncology, 2008-12, Vol.2 (4), p.327-339

2008

Volltextzugriff (PDF)

Transcriptional Repression of Catalase in Mouse Skin Tumor Progression

Neoplasia (New York, N.Y.), 2004-09, Vol.6 (5), p.440-448

2004

Volltextzugriff (PDF)

Catalase reverses tumorigenicity in a malignant cell line by an epidermal growth factor receptor pathway

Free radical biology & medicine, 2006-03, Vol.40 (5), p.863-875

2006

Volltextzugriff (PDF)

The role of Rac1 in maintaining malignant phenotype of mouse skin tumor cells

Cancer letters, 2006-01, Vol.231 (2), p.326-338

2006

Volltextzugriff (PDF)

Attenuation of catalase activity in the malignant phenotype plays a functional role in an in vitro model for tumor progression

Cancer letters, 2001-11, Vol.173 (2), p.115-125

2001

Volltextzugriff (PDF)

Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B‐cell lymphoma

American journal of hematology, 2020-01, Vol.95 (1), p.18-27

2020

Volltextzugriff (PDF)

B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy

Clinical cancer research, 2023-08, Vol.29 (16), p.3065-3073

2023

Volltextzugriff (PDF)

Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis

Blood advances, 2020-11, Vol.4 (22), p.5773-5784

2020

Volltextzugriff (PDF)

Genomic and functional analysis identifies CRKL as an oncogene amplified in lung cancer

Oncogene, 2010-03, Vol.29 (10), p.1421-1430

2010

Volltextzugriff (PDF)

Rarity of B-Cell Receptor Pathway Mutations in Progression-Free Patients With Chronic Lymphocytic Leukemia (CLL) During First-Line Versus Relapsed/Refractory (R/R) Treatment With Ibrutinib

Blood, 2020-11, Vol.136 (Supplement 1), p.32-33

2020

Volltextzugriff (PDF)

Outcomes of First-Line Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and iLLUMINATE)

Blood, 2020-11, Vol.136 (Supplement 1), p.25-26

2020

Volltextzugriff (PDF)

Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies

Leukemia & lymphoma, 2022-06, Vol.63 (6), p.1375-1386

2022

Volltextzugriff (PDF)

Abstract 3833: Systematic evaluation of transcriptome sequencing shows comparable profiles for an exome-capture method for formalin-fixed, paraffin-embedded (FFPE) breast cancer tissues and the standard poly-A method for matched fresh frozen (FF) tissues

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.3833-3833

2017

Volltextzugriff (PDF)

Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma

Leukemia & lymphoma, 2021-07, Vol.62 (9), p.2094-2106

2021

Volltextzugriff (PDF)

Phase 2 Results of the iR2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Blood, 2019-11, Vol.134 (Supplement_1), p.761-761

2019

Volltextzugriff (PDF)

Recurrent rearrangements of the Myb/SANT-like DNA-binding domain containing 3 gene

PloS one, 2017-02, Vol.12 (2), p.e0171265

2017

Volltextzugriff (PDF)

1 – 25 von 78

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(70)
Mit Volltextzugriff
(70)

Publikationsform

Sprache

Englisch
(78)
Japanisch
(12)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery

Identification of recurrent SMO and BRAF mutations in ameloblastomas

Recurrent rearrangements of the Myb/SANT-like DNA-binding domain containing 3 gene (MSANTD3) in salivary gland acinic cell carcinoma

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial

Integrative Genomics Implicates EGFR as a Downstream Mediator in NKX2-1 Amplified Non-Small Cell Lung Cancer

Modulators of sensitivity and resistance to inhibition of PI3K identified in a pharmacogenomic screen of the NCI-60 human tumor cell line collection

SMURF1 amplification promotes invasiveness in pancreatic cancer

Genomic profiling identifies GATA6 as a candidate oncogene amplified in pancreatobiliary cancer

Genomic instability in breast cancer: Pathogenesis and clinical implications

CAMK1D amplification implicated in epithelial–mesenchymal transition in basal-like breast cancer

Transcriptional Repression of Catalase in Mouse Skin Tumor Progression

Catalase reverses tumorigenicity in a malignant cell line by an epidermal growth factor receptor pathway

The role of Rac1 in maintaining malignant phenotype of mouse skin tumor cells

Attenuation of catalase activity in the malignant phenotype plays a functional role in an in vitro model for tumor progression

Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B‐cell lymphoma

B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy

Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis

Genomic and functional analysis identifies CRKL as an oncogene amplified in lung cancer

Rarity of B-Cell Receptor Pathway Mutations in Progression-Free Patients With Chronic Lymphocytic Leukemia (CLL) During First-Line Versus Relapsed/Refractory (R/R) Treatment With Ibrutinib

Outcomes of First-Line Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and iLLUMINATE)

Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies

Abstract 3833: Systematic evaluation of transcriptome sequencing shows comparable profiles for an exome-capture method for formalin-fixed, paraffin-embedded (FFPE) breast cancer tissues and the standard poly-A method for matched fresh frozen (FF) tissues

Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma

Phase 2 Results of the iR2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Recurrent rearrangements of the Myb/SANT-like DNA-binding domain containing 3 gene

Suchergebnisse filtern